shine-logo

Molybdenum-99

Home » Molybdenum-99

SHINE Europe B.V. Designing Advanced Medical Isotopes Facility in the Netherlands

A leader in nuclear technology obtains funding to produce medical isotopes in Europe and to help meet growing demands to provide diagnostic imaging for life-threatening diseases on a global scale.

2022-02-01T17:57:14-06:00February 2, 2022|News, News Releases, 2022|

SHINE and Department of Energy Sign First-ever Contracts Under Uranium Lease and Take-back Program for Molybdenum-99

Vital medical radioisotope used in over 40,000 medical diagnostic procedures [...]

2022-03-09T09:23:37-06:00January 6, 2022|News, News Releases, 2022|

SHINE Medical Technologies Closes $150-million Series C-5 Financing

SHINE Medical Technologies LLC today announced that it has closed a $150-million Series C-5 financing. Koch Disruptive Technologies (KDT) led the round, which also included participation by Fidelity Management & Research Company, Baillie Gifford and other new and current investors.

2021-12-17T17:35:59-06:00June 28, 2021|News, News Releases, 2021|

SHINE, Phoenix merger focused on advancing fusion technology 

JANESVILLE and FITCHBURG, Wis., April 20, 2021 – SHINE Medical Technologies LLC and Phoenix LLC today announced that the companies have completed a merger under which Phoenix has become a wholly owned subsidiary of SHINE.

2021-12-17T17:37:03-06:00April 20, 2021|News, News Releases, Nuclear Fusion, 2021|

SHINE announces weathertight production facility

SHINE Technologies announced that construction of the exterior structure of its first-of-a-kind medical isotope production facility is complete and the building has been certified as weathertight, a major milestone with significance for SHINE.

2021-12-17T17:37:36-06:00March 25, 2021|News, News Releases, 2021|

SHINE closes $80-million

SHINE Medical Technologies LLC, a nuclear technology company focused on becoming the world’s leading producer of medical isotopes, announced today that it has closed an $80-million Series C financing. Fidelity Management and Research Company LLC was the largest investor in the round, which also included participation from other new investors and the company’s current investors.

2021-12-16T20:07:17-06:00September 3, 2020|News, News Releases, 2020|

NRC issues review schedule for SHINE application

SHINE Medical Technologies LLC today announced that the U.S. Nuclear Regulatory Commission (NRC) expects to make a final determination regarding the issuance of an operating license to SHINE by October 2021. SHINE’s application for a license to operate the medical isotope production facility that it is building in Janesville, Wis., was accepted and docketed by the NRC last October.

2021-12-17T17:40:23-06:00May 11, 2020|News, News Releases, 2020|

SHINE & Phoenix Combine for World Record

Phoenix and SHINE Achieve New World Record for Strongest Nuclear Fusion Reaction in a Steady-State System. Leading nuclear technology companies collaborating to help turn nuclear weapons into medicine and help a billion patients. Breakthrough has potential to transform medical isotope production, solve a global health care shortage, provide a stepping stone to cleaner, safer, more abundant energy

2021-12-17T17:42:35-06:00October 2, 2019|News, News Releases, Archived, Neutron Generators, 2019|
Go to Top